CN101301285A - Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition - Google Patents
Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition Download PDFInfo
- Publication number
- CN101301285A CN101301285A CNA2008100926372A CN200810092637A CN101301285A CN 101301285 A CN101301285 A CN 101301285A CN A2008100926372 A CNA2008100926372 A CN A2008100926372A CN 200810092637 A CN200810092637 A CN 200810092637A CN 101301285 A CN101301285 A CN 101301285A
- Authority
- CN
- China
- Prior art keywords
- akg
- purposes
- analog
- mixture
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 80
- 239000008103 glucose Substances 0.000 title claims abstract description 80
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 title abstract description 12
- 208000002720 Malnutrition Diseases 0.000 title description 11
- 235000000824 malnutrition Nutrition 0.000 title description 11
- 230000001071 malnutrition Effects 0.000 title description 11
- 208000015380 nutritional deficiency disease Diseases 0.000 title description 11
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 title 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 150000001413 amino acids Chemical class 0.000 claims abstract description 73
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 44
- 208000024891 symptom Diseases 0.000 claims description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 32
- 241000271566 Aves Species 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 17
- 239000002778 food additive Substances 0.000 claims description 17
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 15
- 239000003674 animal food additive Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000282472 Canis lupus familiaris Species 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 241000283984 Rodentia Species 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 241000699670 Mus sp. Species 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000700199 Cavia porcellus Species 0.000 claims description 6
- 235000021055 solid food Nutrition 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 45
- 239000002207 metabolite Substances 0.000 abstract description 31
- 241000124008 Mammalia Species 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 238000001179 sorption measurement Methods 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 description 71
- 235000001014 amino acid Nutrition 0.000 description 70
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 54
- 210000002381 plasma Anatomy 0.000 description 54
- 210000003240 portal vein Anatomy 0.000 description 47
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 34
- 241001597008 Nomeidae Species 0.000 description 28
- 102000004877 Insulin Human genes 0.000 description 27
- 108090001061 Insulin Proteins 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 229940125396 insulin Drugs 0.000 description 27
- 206010012601 diabetes mellitus Diseases 0.000 description 26
- 229960003136 leucine Drugs 0.000 description 26
- 238000010521 absorption reaction Methods 0.000 description 25
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 22
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 22
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000004202 carbamide Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 17
- 235000013877 carbamide Nutrition 0.000 description 17
- 238000001802 infusion Methods 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 16
- 201000001421 hyperglycemia Diseases 0.000 description 16
- 235000013922 glutamic acid Nutrition 0.000 description 15
- 239000004220 glutamic acid Substances 0.000 description 15
- 208000001647 Renal Insufficiency Diseases 0.000 description 14
- 201000006370 kidney failure Diseases 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 13
- 229960002743 glutamine Drugs 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 210000001198 duodenum Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 229960002429 proline Drugs 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 239000003797 essential amino acid Substances 0.000 description 10
- 235000020776 essential amino acid Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 150000005693 branched-chain amino acids Chemical class 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- 150000004715 keto acids Chemical class 0.000 description 9
- 239000004375 Dextrin Substances 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 8
- 208000013016 Hypoglycemia Diseases 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 235000019425 dextrin Nutrition 0.000 description 8
- 229960003646 lysine Drugs 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 208000032841 Bulimia Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- -1 compound of isomers Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010004716 Binge eating Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 208000014679 binge eating disease Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 210000001842 enterocyte Anatomy 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 210000002989 hepatic vein Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical class S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005891 transamination reaction Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- QRKUHYFDBWGLHJ-UHFFFAOYSA-N N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide Chemical compound FC(F)(F)C(=O)N(C)[Si](C)(C)C(C)(C)C QRKUHYFDBWGLHJ-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940112611 glucovance Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a method for improving adsorption of amino acids in a vertebrate, including mammal and bird, as well as compositions for use in treatment. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable desire effect. AKG, AKG derivatives or metabolites, AKG analogues or mixture thereof. Also conteplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixture thereof, for decreasing glucose adsorption.
Description
The application is to be on July 1st, 2004 applying date, and application number is 200480020322.7, and the invention exercise question is divided an application for " α-Tong Wuersuan is used for the treatment of the purposes of malnutrition or high plasma glucose symptom ".
Technical field
The present invention relates to be used for improving the method for amino acid whose absorption the vertebrates that comprises mammal and birds, and the method that is used to reduce glucose absorption.The invention still further relates to the production that is used for improving the compositions that described vertebrates aminoacid absorbs.
Background of invention
Diabetes are serious metabolic diseases, and it is to determine by the appearance of the plasma glucose content of chronic rising.The classical symptom of adult's diabetes is polyurias, excessive thirst, beta-oxybutyria, the plasma glucose of weight loss and higher level fast.
Normal fasting plasma glucose concentration is for being lower than every liter of 115mg/dl.In diabetics, find that fasting concentration is above 140 milligrams every liter.Generally, diabetes are that β cells injury owing to pancreas occurs.This damage may be owing to primary diabetes mellitus occurs, wherein, the β cell is by the autoimmune system destruction or as the secondary diabetes reaction at other primary diseases, as pancreatic diseases, not owing to lack the hormone abnormality of insulin action, medicine or chemical induction, Insulin receptor INSR is unusual, hereditary symptom or other.
Primary diabetes mellitus can be classified as type i diabetes (be known as not only insulin-dependent diabetes or IDDM) and type ii diabetes (but also being known as noninsulindependent diabetes or NIDDM).
The I type, teenager outbreak or insulin-dependent diabetes are well-known hormone defect states.Wherein, as if pancreatic beta cell is destroyed by the immune defence mechanism of health self.It is rare or do not have an endogenous insulin secretion ability to suffer from the patient of type i diabetes.Extreme hyperglycemia can appear in these patients.Type i diabetes is fatal, introduced insulin substitution and treat-use the insulin from animal origin first before about 70 years, recently, uses the insulin human by the recombinant DNA technology preparation.Clear now, the destruction of β cell has caused two kinds of hormones, the defective of the combination of insulin and dextrin in the type i diabetes.When pancreatic cell is destroyed, the Disability of excreting insulin and dextrin.
The character of pancreatic beta cell damage it be unclear that in type ii diabetes.Different with type i diabetes patient's pancreatic beta cell, type ii diabetes patient's β cell has kept the ability of synthetic and excreting insulin and dextrin.Type ii diabetes is a feature with insulin and resistance, that is, normal metabolic response can not be made to the effect of insulin by peripheral tissues.In other words, insulin resistance is a kind of like this symptom, and wherein, the circulation insulin has produced subnormal biologically.Clinically, but show at insulin and show when continuing normal or higher plasma glucose content and have insulin resistance in the face of normal or higher level.The hyperglycemia relevant with type ii diabetes be sometimes can by diet recover or alleviate or lose weight and be enough to recover the sensitivity of peripheral tissues insulin.In fact, type ii diabetes is usually being feature in the hyperglycemia that occurs being higher than under the plasma insulin condition of normal level.The development of type ii diabetes is relevant with the high concentration plasma glucose, and with the relative reduction of the insulin secretion speed of glucose induction.Therefore, for example,, may there be insulin deficit in the late period of type ii diabetes.
Known treating diabetes and prevention
The main purpose of treatment all types diabetes is identical, being about to plasma glucose concentration is reduced to as much as possible near normal level, thereby reduce the short-term and the long-term complications (Tchobroutsky, Diabetologia 15:143-152 (1978)) of this disease.
Relation between the order of severity of the hyperglycemia of diabetics and the caused long-term complications is verified further by the DCCT (DCCT) that National Institutes of Health (The Diabetes Control andComplications Trial Research Group, N.Eng.J.Med.329:977 (1993)) finishes recently.DCCT carried out in the U.S. and Canadian 29 clinical center with 10 years, had confirmed to reduce type i diabetes patient's average blood plasma concentration of glucose, had reduced final organ complication.Retinopathy reduced by 76%, the development of retinopathy has reduced by 54%, and the index of nephropathy (albuminuria, albuminuria) is alleviated to some extent.Significantly the generation of neuropathy reduces equally.
The treatment of type i diabetes must relate to uses the insulin that recovers dosage, uses by parenteral route.Combine with correct diet and the monitoring of self-plasma glucose, most of type i diabetes patient can obtain the control to a certain degree to plasma glucose.
Opposite with type i diabetes, the treatment of type ii diabetes does not need to use insulin usually.The therapeutic scheme of type ii diabetes is usually directed to Diet Therapy test and life style adjustment, at first carries out the 6-12 time-of-week usually.
It is suitable that the feature of diabetics diet comprises, but be not excessive total calorie picked-up, clocklike has meal, and limits the content of saturated fat, increases the content of polyunsaturated fatty acid simultaneously, and the picked-up that increases dietary fiber.
Life style changes the motion that comprises that maintenance is frequent, as the supplementary means of start-up control and minimizing insulin resistance degree.
If after suitable diet test and life style change, still there is the fasting hyperglycemia, just can make the diagnosis of " constitutional dietary deficiency ", and the Steering Body that needs oral blood sugar lowering therapeutic test or directly insulinize need produce plasma glucose control, and therefore reduces the complication of this disease.The type ii diabetes patient that can not react to diet and losing weight may be to using oral hypoglycemic, reacts as the treatment that sulfonylureas or biguanide are carried out.But, insulinize is used to treat other patients that suffer from type ii diabetes, constitutional dietary deficiency and NO patient have particularly occurred or the constitutional dietary deficiency occurred and the patient of Secondary cases blood sugar lowering failure.
At U.S. Patent number 5,124, disclosed in 314 and 5,175,145 the dextrin stimulant has been used for the treatment of diabetes.The new Therapeutic Method that is used as of excessive dextrin that Simulation with I type i diabetes and dextrin are suppressed has been proposed.
For example, known treatment has the diabetes pill, and for example, based on the pill of sulfonylureas, it helps pancreas to produce more insulin, and helps health to use insulin better.Possible side effect: hypoglycemia, stomach-ache, erythra or pruritus and weight increase.
Can limit the glucose generation of liver based on other pills of biguanide, and can reduce the amount of insulin in the health equally, improve blood fat and cholesterol state.Possible side effect has the vomiting with the ethanol combination, has increasing the weight of of kidney and disease now, weakness, and dizziness, dyspnea is felt sick, and diarrhoea.
The enzyme that can suppress digestible starch based on other pills of alpha-glucosidase inhibitor.Possible side effect has gastrointestinal problems.
Other pills based on thiazolidinedione help cell more responsive for insulin.Possible side effect is, they can not be used in combination (making regular check on) with hepatic disease, and hypoglycemia and can only making up with other treatment can not pass through pill birth control, weight increase, anemia danger, swelling (edema) effectively.
Help pancreas with producing more insulin after the meal based on other pills of meglitinide.Possible side effect is a hypoglycemia, and weight increase.
In addition, exist the mouth of combination to use medicine, for example, based on glyburide (sulfonylureas) and metformin (biguanide), for example, " Glucovance ".Possible side effect is a hypoglycemia, can not use simultaneously with nephropathy, and can not be used in combination with ethanol.
US 5,234, and 906 have disclosed the compositions that comprises glucagon and dextrin stimulant, and they are used to control or treat the purposes of hyperglycemia symptom.
WO 93/10146 has disclosed the dextrin stimulant, and uses it for treatment or prevention hypoglycemia symptom, comprises the symptom that needs insulin, as the purposes of diabetes.
Renal failure and malfunction
Renal failure or kidney malfunction are the states that kidney can not be removed intravital refuse.Renal failure has caused the accumulation of deleterious refuse in blood.Kidney has extra removing ability usually, and before symptom occurring, the ability of kidney have 50% normal.Symptom comprises pruritus, and fatigue is felt sick, vomiting, and inappetence causes malnutrition.Renal failure is relevant with diabetes and hypertension usually.In suffering from the object of renal failure, above-mentioned symptom appears, that is and, vomit and cause underfed inappetence.
Dialysis process can alleviate from the pressure of refuse to kidney.In addition, it is the method for spended time.The patient may need to carry out weekly the several treatment.Carry out the needs of patients medical attention of dialysis treatment, and this method is cost and time loss type.
Glucose oxidation
From the original position rat studies that Windmueller and Spaeth (1) carry out, known glutamic acid and glutamine are the important metabolism fuel of small intestinal.Windmueller and Spaeth have reported during absorbing first by the metabolism of intestinal to the vast scale of glutamic acid (95%) and glutamine (70%).Their result has obtained checking in vivo on piglets (2) and people (3).
During glucose oxidation, first step is the transamination of being undertaken by any amount of enzyme, and by the deaminizating that glutamte dehydrogenase (GDH) carries out, a lot of enzymes are wherein expressed (4,5) in gastrointestinal tract.The deaminizating that is undertaken by GDH has produced AKG and free ammonia.During the transamination of being undertaken by branched-amino transferring enzyme (BCAT), glutamic acid partly offers branched-chain alpha-ketoacid with amino, has formed AKG and corresponding branched-chain amino acid.
α-Tong Wuersuan
Glutamine and derivant thereof, for example, α-Tong Wuersuan (AKG) is the molecule that has pivotal role in systematicness of being undertaken by tricarboxylic acid cycle and intestinal metabolism.But, its mechanism of action is still not exclusively understood (Pierzynowski, S.G., and Sjodin, A. (1998) J.Anim.a.Feed Sci.7:79-91; With Pierzynowski S.G., wait Eds:KBK Knutsen and J-E Lindberg., Uppsala 19-21 June, 2001).
Theoretically, AKG (2-oxygen-1,3-propanedicarboxylic acid, 2-oxoglutaric acid, α-Tong Wuersuan, α-oxygen-1,3-propanedicarboxylic acid, 2-oxoglutaric acid, 2-oxygen-1,5-1,3-propanedicarboxylic acid, 2-oxygen-1,3-propanedicarboxylic acid, 2-oxoglutaric acid) may be glutamine, glutamate, Glu, the product of glutamic acid internal metabolism degraded.In addition, it can also not only play a part glutamine and arginic precursor, but also can be used as some other amino acid whose precursor, therefore, is considered to the metabolic protective agent of albuminolysis.Olin etc., 1992 when having confirmed in fish meal to add AKG, the carbamide of discharge has reduced.Similarly; in human body; in total parenteral absorption (TPN) solution, add AKG and amino-acid mixed fashionable with other; after operation, observed good protective action (Pierzynowski to nitrogen loss; S.G.; and Sjdin, A. (1998) J.Anim.a.Feed Sci.7:79-91).For the mankind, AKG may degrade with muscle protein and combine, to satisfy the demand of intestinal during coercing after the so-called operation, for example, catabolism, hunger etc.
Function of intestinal canal has obtained the confirmation (1996 of Reeds etc. recently to the demand of the relevant metabolite of glutamine family, Am.J.of Physiol.-Endocrinology and Metabolism270:413-418), this author has reported in operation 100% glutamic acid/glutamine utilization rate almost during by newborn piglet small intestinal.
AKG may be important energy donor, by a few path for transformation, for example forms GABA or succinate by ornithine and putrescine.Theoretically, AKG can also play a part the ammonium ion scavenger, may be by transforming to glutamic acid/glutamine.
Have realized that-but still unexposed mistake-enterocyte depends on their growths from ammonium.
Therefore, consider the problems referred to above, the needs exploitation is used for the treatment of and prevents mammal especially, for example, and cat, Canis familiaris L. or human hypoglycemia symptom, as diabetes, and the malnutrition relevant with diabetes, for example apparatus and method of renal failure, wherein, can avoid with the problem or the side effect of existing apparatus and method.In addition, except the nutritional status of nephrotic and diabetes, also need to improve health status.At this on the one hand, the present invention has satisfied above-mentioned needs and advantage.
Summary of the invention
Consider above-mentioned in prevention, known problem and be used for the treatment of and be used to proofread and correct the malnutrition relevant with renal failure in treatment and/or diabetes-alleviating and other hypoglycemia relevant disease fields with for example diabetes, the invention provides and be used for prevention, treatment and/or diabetes-alleviating and underfed new and method and composition improvement.
An object of the present invention is to provide the method that is used to improve the vertebrate aminoacid absorption that comprises mammal and birds.This method comprises to the vertebrates that comprises mammal and birds, uses AKG with enough quantity and/or enough speed, AKG derivant or metabolite, and AKG analog or its mixture are so that can absorb the effect of wishing that produces to aminoacid.
A kind of embodiment of described method is such, wherein, described AKG, AKG derivant or metabolite, AKG analog or its mixture are selected from following one group: one of the salt of other of α-Tong Wuersuan (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, chitosan-AKG, AKG and aminoacid and amino acid derivativges, AKG-and two-slaine, as CaAKG, Ca (AKG) 2 and NaAKG.
Another embodiment is such, and wherein, described vertebrates is a rodent, as mice, and rat, Cavia porcellus or rabbit; Birds, as turkey, hen, chicken or other chickling; Farm animal, as cow, horse, pig, the farm animal that piglets or other are freely walked about; Or house pet, as Canis familiaris L. or cat.
Another embodiment is such, and wherein, described vertebrates is human.
Another embodiment is such, and wherein, described aminoacid is any essential amino acids.
A kind of embodiment in sea is such, and wherein, described essential amino acids is an isoleucine, leucine, lysine, and proline.
The present invention also comprises the method that is used to reduce the vertebrate glucose absorption that comprises mammal and birds.This method comprises to the vertebrates that comprises mammal and birds uses AKG with enough quantity and/or enough speed, AKG derivant or metabolite, and AKG analog or its mixture are so that can produce the influence that needs to glucose absorption.
The present invention also comprises and is used for preventing, suppresses or alleviate the method for the vertebrate high glucose symptom that comprises mammal and birds.This method comprises to the vertebrates that comprises mammal and birds, uses AKG with enough quantity and/or enough speed, AKG derivant or metabolite, and AKG analog or its mixture are so that can produce the influence that needs to described symptom.
A kind of embodiment is such, and wherein, described high glucose symptom is I type or type ii diabetes.
The present invention also comprises AKG, AKG derivant or metabolite, and AKG analog or its mixture production are used to prevent, alleviate or treat the purposes of the compositions of high glucose symptom.
A kind of embodiment is such, and wherein, described high glucose symptom is I type or type ii diabetes.
The invention still further relates to AKG, AKG derivant or metabolite, AKG analog or its mixture production are used to prevent, alleviate or treat the purposes of underfed compositions.
A kind of embodiment of described purposes is such, and wherein, described compositions is a Pharmaceutical composition, and optionally comprise can be medicinal carrier and/or additive.
The another embodiment of described purposes is such, and wherein, described compositions is food or feed additive.
Another embodiment is such, and wherein, described food or feed additive are the compositions of food additive and/or solid food and/or drink form.
Another embodiment is such, and wherein, at AKG described in the compositions of producing, AKG derivant or metabolite, AKG analog or its mixture are to treat effective dose.
Another embodiment is such, and wherein, described treatment effective dose is 0.01-0.2g/kg body weight dosage every day.
Brief description of drawings
Fig. 1 is illustrated in contrast and the intravital whole leucine kinetics of AKG infusion pig.Value is mean value SEM; N=9, each pig is accepted contrast and AKG.When carrying out error analysis (ANOVA), value and the contrast of AKG do not have difference.AKG represents α-Tong Wuersuan; On behalf of non-oxidizable leucine, NOLD handle; On behalf of leucine, Ra speed occurs; Balance, promptly Ra deducts from NOLD, expression albuminous body leucine balance.
Detailed description of the invention
Definition
In the context of the application and invention, used to give a definition:
In this article, the effective composition of term " Pharmaceutical composition " expression treatment of the present invention.
In this article, term " treatment effective dose " or " effective dose " or " treatment effectively ", expression can be to the consumption of specific symptoms and application program generation result for the treatment of. It is the scheduled volume that calculates the active material that can produce the desirable therapeutic action relevant with diluent with the additive of needs; That is, carrier or application media. In addition, it also can be used for expression is enough to alleviate, and most preferably prevents host's activity, the consumption of the remarkable defective on the clinical medicine of function and reaction. In addition, the treatment effective dose is the improvement that is enough to cause host's clinical remarkable symptom. As is understood by persons skilled in the art, the consumption of compound can change according to its specific activity. Suitable dosage can comprise the active compound of scheduled volume, and it is calculated and can produces the desirable result for the treatment of relevant with the diluent of needs; That is, carrier or additive. In method and purposes for the production of composition of the present invention, provide the active component for the treatment of effective dose. The treatment effective dose can be definite according to patient's feature by common doctor or veterinary work person, such as the age, and body weight, sex, symptom, complication, other diseases etc. are as known in the field.
In this article, term " derviate " or " derivative " expression is directly or by modifying or part replaces chemical substance from parent.
In this article, similar each other on term " analog " or " analog " the expression structure, but the compound of isomers not necessarily. Analog has similar function, but different on structure or the origin of evolving.
In this article, the processing of " treatment " expression take healing as purpose, it may be symptom fully/comprehensively or part cure.
In this article, the intensity of mitigation symptoms is not only in term " alleviation " expression, but also has postponed the outbreak of symptom.
In this article, term " prevention " expression guarantees that some event can not occur, and for example, the symptom relevant with jejune GIT can not occur. By preventing some symptom, can postpone the generation of described symptom.
In this article, term " Amino Acid Absorption that increases " expression is compared with the vertebrate of not accepting treatment of the present invention or use, change has occured in vertebrate amino acid whose clean absorption, if compare with the vertebrate of the identical type of not accepting described treatment, larger in the clean amount that absorbs described in the described vertebrate, just think that described change is to strengthen.
In this article, the reading of vertebrate amino acid and glucose absorption is monitored or is measured in term " dynamics " expression continuously or often, in order to determine its infiltration rate.
In this article, term " sodium-AKG " can with term " AKG-Na ", " Na-AKG ", " sodium salt of AKG ", " AKG (sodium salt) " exchange is used.
In this article, term " chitosan-AKG " can with term " AKG-chitosan ", " AKG (chitosan salts) " exchange is used.
The diagnosis of I type and type ii diabetes
The diagnosis of suffering from the patient of I type and type ii diabetes belongs to those skilled in the art's ability and the scope of knowledge. For example, the age surpasses 35 years old, has polydipsia, polyuria, and baulimia (be with or without and lose weight) and relevant with higher plasma glucose concentration, and do not have the individuality of the medical history of ketone acid usually to be diagnosed as type ii diabetes. Fat appearance, the Positive family history of type ii diabetes, and normal or higher fasting plasma insulin and c-peptide concentration are other features of suffering from the Most patients of type ii diabetes. The consumption of " treatment effective dose " one or more dosage of expression, it preferably can reduce the plasma glucose concentration of the object of suffering from type ii diabetes.
The inventor finds amazedly that absorption has impact on AKG in infusion site. After duodenum is inculcated AKG, the glucose absorption of having observed in surprise the Amino Acid Absorption that has strengthened and having weakened.
Therefore, the present invention can be used for reducing the plasma glucose of non--insulin-absorption type ii diabetes object.
Underfed diagnosis
Suffer from underfed patient, promptly can not suitably take in nutrition or underfed diagnosis, belong to those skilled in the art's the ability and the scope of knowledge.Usually, the general health state of individuality is assessed, so that determine malnutrition.
The diagnosis of renal failure
The diagnosis of suffering from the patient of renal failure belongs to those skilled in the art's the ability and the scope of knowledge.
The renal failure that two kinds of forms are arranged, acute and chronic renal failure (ACF and CRF).Acute renal failure normally can be recovered, and chronic renal failure normally develops.CRF can be distinguished into pre-dialysis and uremic active treatment, for example, uses dialysis or transplanting.Do not have the definite restriction of the starting point of pre-dialysis, but, pre-usually dialysis is confirmed as diagnosing out the time between renal failure and the beginning active treatment.
Dialysis and transplanting are considered to active treatment.
Improve the method that aminoacid absorbs
According to the present invention, disclosed the method that is used to improve the vertebrate aminoacid absorption that comprises mammal and birds.This method comprises to the vertebrates that comprises mammal and birds, uses AKG with enough quantity and/or enough speed, AKG derivant or metabolite, and AKG analog or its mixture produce the influence that needs so that can absorb aminoacid.
Described aminoacid is absorbed in and does not accept described AKG, AKG derivant or metabolite, and the vertebrate aminoacid that comprises mammal and birds of AKG analog or its mixture absorbs and is considered to improve when comparing.
The another embodiment of described method is such, wherein, described AKG, AKG derivant or metabolite, AKG analog or its mixture are selected from following one group: α-Tong Wuersuan (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, chitosan-AKG, the salt of other of AKG and aminoacid and amino acid derivativges; One of AKG-and two-slaine, as CaAKG, CaAKG
2, and NaAKG.
Other embodiments are such, and wherein, described vertebrates is a rodent, as mice, rat, Cavia porcellus or rabbit; Birds is as turkey, hen, chicken or other chickling; Farm animal is as cow, horse, pig, piglets or the farm animal of freely walking about; Or house pet, as Canis familiaris L. or cat.
Another embodiment is such, and wherein, described vertebrates is human.The described mankind need the underfed patient of treatment, described malnutrition be because, for example, renal failure, diabetes, the athlete, age (child and old people), pregnancy, anorexia nervosa, bulimia, binge eating, the eating disorder that mandatory binge eating or other are not pointed out (EDNOS).
In another embodiment, described vertebrates as the people, can be any vertebrates that needs to increase amino acid whose utilizability and availability, for example, and essential amino acids or condition aminoacid, particularly isoleucine, leucine, lysine and proline.
The example of essential amino acids is an a-amino acid, as being isoleucine (Ileu) in human body, leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), threonine (Thr), tryptophan (Try) and valine (Val).Essential amino acids between the species is different.Rat needs two kinds of other aminoacid, i.e. arginine (Arg) and histidine (His).
Other embodiments are such, and wherein, described aminoacid is any aminoacid, as alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, threonine, cystine, tyrosine, glutamine, histidine, lysine, arginine, aspartic acid, agedoite, glutamic acid, glutamine, glycine and serine.
Other embodiments are such, and wherein, described aminoacid is any essential or condition essential amino acids.Example essential or the condition essential amino acids is as shown in table 2.
Another embodiment is such, wherein, described must or the condition essential amino acids be selected from following one group: isoleucine, leucine, lysine and proline.
Be used to reduce the method for glucose absorption and be used for prevention, suppress or alleviate the method for plasma glucose increase
Plasma glucose content is the content of glucose in the blood (sugar).It is also called serum glucose level.The content of glucose is expressed as every liter of mM (mmol/l) or mg/dL in the blood.
Usually, in human body, plasma glucose content remained in one day in the narrow bound scope, approximately 4-8mmol/l.Glucose content after having meal is higher, and minimum in the morning.Be typically about 70-110mg/dL (3.9-6.1mmol/L) during fasting, and after having meal 2 hours, be typically about 80-140mg/dL (4.4-7.8mmol/L).(>10.0mmol/l) plasma glucose content is considered to the high plasma glucose value to 2 hours>180mg/dL after having meal usually.When fasting, when plasma glucose value>140mg/dL, also be this situation.
If a people for example suffers from, diabetes, their plasma glucose content sometimes may exceed the above-mentioned limit.It is lower that all diabetes patients' basic defect is that insulin-induced soma is removed the ability of glucose (sugar) molecule from blood.No matter this lower insulin active be because the minimizing (for example, type i diabetes) of the amount of the insulin that is produced or since cell to the insulin insensitivity of normal contents, consequently identical, that is, the plasma glucose too high levels.It is known as " hyperglycemia " or " hyperglycemia " or " hyperglycemia ", and it represents " the high glucose in the blood ".Usually, when plasma glucose>240mg/dL (>just be considered to hyperglycemia 13.4mmol/L) time.
According to the present invention, disclosed and be used to weaken the method that the vertebrates that comprises mammal and birds absorbs at interior plasma glucose.This method comprises to the vertebrates that comprises mammal and birds, uses AKG with enough quantity and/or enough speed, AKG derivant or metabolite, and AKG analog or its mixture are so that can produce the influence that needs to the absorption of glucose.
Using AKG, AKG derivant or metabolite, after AKG analog or its mixture, the minimizing of glucose absorption can be for the 5-50% of initial plasma glucose value, as 5,10,15,20,25,30,35,40,45 or 50%.
In another embodiment, the 20-40% that is reduced to initial plasma glucose value of described absorption.
In another embodiment, described 30% of the initial plasma glucose value that is reduced to.
In addition, disclosed and be used for prevention, suppressed or alleviated the method for the vertebrate high plasma glucose symptom that comprises mammal and birds.Described method comprises to the vertebrates that comprises mammal and birds, use AKG with enough quantity and/or enough speed, AKG derivant or metabolite, AKG analog or its mixture are so that can produce ideal effect to described high glucose symptom.
In another embodiment, described high glucose symptom is the hyperglycemia symptom.
The described method relevant with high glucose or hypoglycemia comprises other embodiments, wherein, described AKG, AKG derivant or metabolite, AKG analog or its mixture, be selected from following one group: α-Tong Wuersuan (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, the salt of other of chitosan-AKG, AKG and aminoacid and amino acid derivativges; One of AKG-and two-slaine, as CaAKG, CaAKG
2And NaAKG.
Other embodiments are such, and wherein, described vertebrates is a rodent, as mice, rat, Cavia porcellus or rabbit; Birds is as turkey, hen, chicken or other chickling; Farm animal is as cow, horse, pig, piglets or the farm animal of freely walking about; Or house pet, as Canis familiaris L. or cat.
Other embodiments are such, and wherein, described vertebrates is human.
Other embodiments are such, wherein, described high glucose symptom be because, for example, acromegaly, the glad syndrome of Ke Xing Shi, hyperthyroidism, cancer of pancreas, pancreatitis, pheochromocytoma, insulin content is not enough or too much food intake is too much.
Other embodiments are such, and wherein, described high glucose level causes owing to I type or type ii diabetes.
AKG is used for the treatment of diabetes and is used for the treatment of malnutrition
According to the present invention, disclosed AKG, AKG derivant or metabolite, AKG analog or its mixture production are used to prevent, alleviate or treat the purposes of the compositions of high glucose symptom.
High glucose symptom and hyperglycemia symptom are described in front the paragraph.
Other embodiments comprise that wherein, described hyperglycemia symptom is I type or II diabetes.
According to the present invention, disclose AKG, AKG derivant or metabolite, AKG analog or its mixture production are used to prevent, alleviate or treat the purposes of underfed compositions.
In other embodiments of described purposes, described compositions is a Pharmaceutical composition, it optionally comprise can be medicinal carrier and/or additive.
In other embodiments, described compositions is food or feed additive.
In other embodiments, described food or feed additive are the compositions of food additive and/or solid food and/or drink form.
In other embodiments, the described AKG in the compositions of producing, AKG derivant or metabolite, AKG analog or its mixture are to treat effective dose.
In other embodiments, described treatment effective dose is 0.01-0.2g/kg body weight dosage every day.
Use AKG, AKG derivant or metabolite, AKG analog or its mixture
According to above disclosed method, give the vertebrates that comprises mammal and birds; Rodent is as mice, rat, Cavia porcellus or rabbit; Birds is as turkey, hen, chicken or other chickling; Farm animal is as cow, horse, pig, piglets or the farm animal of freely walking about; Or house pet, use AKG as Canis familiaris L. or cat, AKG derivant or metabolite, AKG analog or its mixture.
Use and can be undertaken, depend on the vertebrate species that will treat, need the vertebrate symptom of described method by diverse ways, and the specific targets that will treat.
In one embodiment, described using with food or feed additive form carried out, as the composition of food additive and/or solid food and/or drink form.Other embodiments can be suspension or solution form, as the beverage of following further disclosure.
In addition, dosage form can comprise capsule or tablet, as masticable or solubility, and for example effervescent tablet, and powder and other dried forms known in those skilled in the art, as bead, as microsphere, granule and powder.
As above disclosed, described using can be parenteral, rectum or oral cavity food or feed additive form.The parenteral medium comprises sodium chloride solution, Ringer ' s glucose, glucose and sodium chloride, lactic acid Ringer ' s or fixed oil.
Described food and feed additive can also be emulsive.Then can be with active treatment composition and mixed with excipients, described excipient can be medicinal, and compatible with described active component.Suitable excipient has, for example, and water, saline, glucose, glycerol or ethanol etc., and their combination.In addition, if necessary, described compositions can contain the auxiliary substance of trace, as wetting agent or emulsifying agent, and the pH buffer agent, they can strengthen the effect of described active component.
Can replenish the different dosage form of parenteral food or feed additive, as solid food, liquid or cryodesiccated or other exsiccant preparations.It can comprise diluent (for example, Tris-HCl, the acetic acid with various cushions, phosphoric acid), pH and ionic strength, additive, as albumin or gel, so that prevent absorption to the surface, detergent (for example, Tween 20, and Tween 80, Pluronic F68, cholate), solubilizing agent, (for example, glycerol, Polyethylene Glycol), antioxidant is (for example, ascorbic acid, sodium pyrosulfite), antiseptic is (for example, thimerosal, benzylalcohol, parabens), filler or osmotic pressure regulator are (for example, lactose, mannitol), such as the polymer of Polyethylene Glycol and the covalent bond of described compositions.Arrive as polylactic acid with the complexation or the described material sorting of metal ion, polyglycolic acid in the granular formulations of the polymer of hydrogel etc. or on it, or is incorporated into liposome, micro emulsion, and micelle, the single or multiple lift vesicle is on erythrocyte umbra or the spheroplast.
Beverage
In one embodiment, described food or feed additive are with beverage or its dry compositions form, use by any method of the present invention.
Described beverage comprises the AKG of effective dose, AKG derivant or metabolite, and AKG analog or its mixture, and acceptable water-solubility carrier in the nutrition, as mineral, vitamin, carbohydrate, fat and albumen.AKG, AKG derivant or metabolite, the example of AKG analog or its mixture have α-Tong Wuersuan (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, the salt of other of chitosan-AKG, AKG and aminoacid and amino acid derivativges; One of AKG-and two-slaine, as CaAKG, CaAKG
2And NaAKG.
If described beverage is to provide with dried forms, above-mentioned all the components all provides with dried forms.The beverage that provides with the form that can directly consume also comprises water.Final drink soln can also have in check osmotic pressure and acidity, as the buffer solution of conduct according to the explanation of the generality in above paragraph preparation.
Preferably in the scope of about 2-5, particularly about 2-4 is so that suppress antibacterial and conk for pH.Can also use sterilized beverage, its pH is about 6-8.
Described beverage can use separately or use with one or more treatment effective composition.
AKG, AKG derivant or metabolite, the purposes of AKG analog or its mixture
According to the present invention, disclosed and used AKG, AKG derivant or metabolite, AKG analog or its mixture production are used for prevention, alleviate or treatment hyperglycemia symptom, as I type and type ii diabetes, and the purposes that is used for the treatment of underfed compositions.
Another embodiment of the present invention comprises purposes, and wherein, described compositions is a Pharmaceutical composition.This Pharmaceutical composition can with carrier and/or additive that can be medicinal, as diluent, antiseptic, solubilizing agent, emulsifying agent, adjuvant and/or carrier one are used from the present invention disclosed method and purposes.
In addition, in this article, " carrier that can be medicinal " is well known to those skilled in the art, and includes, but are not limited to 0.01-0.05M phosphate buffer or 0.8% saline.In addition, described carrier that can be medicinal can be water or non-aqueous solution, suspension and emulsion.The example of nonaqueous solvent has propylene glycol, Polyethylene Glycol, and vegetable oil is as olive oil and the organic ester that can inject, as ethyl oleate.Aqueous carrier comprises water, alcohols/aqueous solution, and emulsion or suspension comprise saline and buffering medium.The parenteral medium comprises sodium chloride solution, Ringer ' s glucose, glucose and sodium chloride, newborn acidifying Ringer ' s or fixed oil.Can also use antiseptic and other additives, for example, anti-microbial agents, antioxidant, chelating agen and noble gas etc.
Another embodiment of the present invention comprises purposes, and wherein, described compositions is the composition of food additive and/or solid food and/or drink form,
The compositions of this production, as Pharmaceutical composition or food or feed additive, comprise compositions of the present invention, and comprise that optionally carrier and/or a certain amount of second kind maybe can influence any hyperglycemia symptom, as I type and type ii diabetes, and underfed other active component.
The dosage of the Pharmaceutical composition of using
According to the present invention, AKG, AKG derivant or metabolite, AKG analog or its mixture are used to produce the purposes of compositions of the present invention, comprise to needs it such as birds or mammiferous vertebrates administering therapeutic effective dose.Described treatment effective dose is about 0.01-0.2g/kg body weight dosage every day.
AKG, AKG derivant or metabolite, AKG analog or its mixture
According to the present invention, comprise AKG, AKG derivant or metabolite, AKG analog or its mixture.AKG, AKG derivant or metabolite, the example of AKG analog or its mixture have α-Tong Wuersuan (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, chitosan-AKG, the salt of other of AKG and aminoacid and amino acid derivativges; One of AKG-and two-slaine, as CaAKG, CaAKG
2, NaAKG.
Application target
As the fine understanding of those of ordinary skills, method of the present invention and Pharmaceutical composition are particularly suitable for using to its any vertebrates of needs, as birds, include, but are not limited to turkey, hen or chicken and other chickling and the animal or the mammal of freely walking about include, but are not limited to, domestic animal is as cat or dog object, farm animal, for example, but be not limited to cattle, horse, he-goat, sheep and pig object, wild animal, no matter be to live in open-air or live in the zoo, zoologize, as mice, rat, rabbit, goat, sheep, pig, Canis familiaris L., cats etc. promptly are used for veterinary's goals of medicine.
In addition, in treatment any high glucose level or hyperglycemia symptom, as I type and type ii diabetes, and for example, when renal failure, any symptom relevant after I type and the type ii diabetes, comprise the mankind as subject with malnutrition.
In addition, described subject can also be any vertebrates, and as one of above-mentioned animal, it need improve amino acid whose effectiveness and utilizability, described aminoacid for example is essential amino acids or condition aminoacid, particularly isoleucine, leucine, lysine and proline.The described mankind can also be the patients who needs the treatment malnutrition or increase amino acid whose effectiveness and utilizability, for example owing to renal failure, and operative treatment, for example, pancreatectomy or transplanting, old symptom, diabetes, athlete, age (child and old people), pregnancy, anorexia nervosa, bulimia, binge eating, mandatory binge eating, nutrition disease, the feed disorder (EDNOS) that metabolism disorder or other are not pointed out, decubital ulcer, the vertebrates of inappetence or because wasting disease.
List of references
(all documents that this paper quoted are all received with their full text form and are done this paper reference).
1.Windmueller,H.G.,& Spaeth,A.E.(1975)Intestinalmetabolism of glutamine and glutamate from the lumen as comparedto glutamine from blood.Arch.Biochem.Biophys.171:662-672.
2.Stoll,B.,Burrin,D.G.,Henry,J.,Hung,Y.,Jahoor,F.,& Reeds,P.J.(1999)Substrate oxidation by the portaldrained viscera of fed piglets.Am.J.Physiol.277:E168-E175.
3.Matthews,D.E.,Marano,M.A.,& Campbell,R.G.(1993)Splanchnic bed utilization of glutamine and glutamic acid inhumans.Am.J.Physiol.264:E848-E854.
4.Madej,M.,Lundh,T.,& Lindberg,J.E.(1999)Activitiesof enzymes involved in glutamine metabolism in connection withenergy production in the gastrointestinal tract epithelium ofnewborn,suckling and weaned piglets.Biol.Neonate 75:250-258.
5.Suryawan,A.,Hawes,J.W.,Harris,R.A.,Shimomura,Y.,Jenkins,A.E.,& Hutsun,S.M.(1998)A molecular modelof human branched-chain amino acid metabolism.Am.J.Clin.Nutr.68:72-81.
6.Lambert,B.D.,Stoll,B.,Niinikoski,H.,Pierzynowski,S.,& Burrin,D.G.(2002)Net portal absorption of enterallyfedal pha-ketoglutarate is limited in young pigs.J.Nutr.132:3383-3386.
7.Kristensen,N.B.,Jungvid,H.,Fernande z,J.A.,&Pierzynowski,S.G.(2002)Absorption and metabolism ofa-ketoglutarate in growing pigs.J.Anim.Physiol.Anim.Nutr.86:239-245.
8.Bergmeyer,H.U.,& Bemt,E.(1974)2-oxoglutarate.UVspectrophotometric determination.In:Methods of enzymaticanalysis,2nd Ed.(Bergmeyer,H.U.,ed.).Academic Press,NewYork,NY
9.Pajor,A.M.(1999)Sodium-coupled transporters forkrebs cycle intermediates.Annu.Rev.Physiol.61:663-682.
10.Murphy,J.M.,Murch,J.M.,and Ball,R.O.(1996)Proline is synthesized from glutamate duringintragastricinfusion but not during intravenous infusion in neonatalpiglets.J.Nutr.126:878-886.
Embodiment
Below will the present invention will be described by a plurality of indefiniteness embodiment.Although the embodiment in conjunction with some disclosure describes the present invention, the technical staff can predict change that still belongs to the appended claims scope or the combination of specifically not mentioning.
Material and the method part of example 1-2
Animal is kept
Stable breeding of animal and nursing meet the regulation of U.S.Department of Agricultureguidelines.
Research design
Female piglets (n=9) is from Texas Department of Criminal Justice, Huntsville, and TX buys.
These pigs (14 days big) arrive Children ' s Nutrition Research Center, and carry out 7 days the phase of adjustment, (Middleton WI) raises for LitterLife, Merrick with liquid formula with the speed of 50g/ (kg.d).
The prescription of described milk replacer (every kilogram of dry): 500g lactose, 100g fat and 250g albumen.
After 7 days, cancel the food of described piglets, spend the night, and allow them perform the preparation (2) that undergos surgery as stated above.
Say that simply under isoflurane anesthesia and aseptic condition, (external diameter is 1.27mm with the polyethylene intubate, Becton Dickinson, Sparks, MD) the common door vein of insertion piglets, and with silicone rubber intubate (external diameter 1.78mm) insertion external jugular vein and carotid artery.
(Ithaca NY) is placed on around the portal vein for internal diameter 8-10mm, Transonic with the ultrasonic flow probe.
With the silicon intubate (external diameter is 2.17mm, Baxter Healthcare, McGaw Park IL) inserts duodenal inner chamber, described intubate is filled and is contained heparin (2.5 * 10
4U/L) Sterile Saline, and from abdominal part left side (portal vein and duodenal intubation, flow probe guiding) or take out by abdomen from (jugular vein and carotid artery intubate) between the scapula.
Before being about to carry out surgical operation, animal is carried out intramuscular injection antibiotic (20mg/kg anthracene Flucloxacillin, Bayer, Shawnee Mission, KS), and intramuscular injection analgesics (0.1mg/kg butorphenol tartrate, Fort Dodge Labs, Fort Dodge, IA).
After operation, recover before the intestinal feed, these pigs were kept 24 hours by comprehensive parenteral absorption, and feed speed is 5mL kg
-1h
-1Allow these pigs from operation, recover with 7 day time.Food intake and weight increase speed return to preoperative level in all piglets bodies.
Sample preparation
Blood sample is placed on ice at once and centrifugal.
Collect blood plasma, at once in liquid nitrogen, and under-80 ℃, preserve up to analysis.
Amino acid analysis
In order to carry out the blood plasma amino acid analysis, the equal portions plasma sample of 0.2mL is mixed with the aqueous solution (4mmol/L) of isopyknic methionine sulfone, and blocked filter centrifugal 120 minutes by 10-kDa with the speed of 10,000 * g.
The described filtrate sample of equal portions of dry 50 μ L, and by reversed-phase HPLC to amino acid whose phenylisothiocyanate, PITC salt derivative analyze (Pico Tag, Waters, Woburn, MA).
Method by improved slightly Brgmeyer and Bernt (8) is measured plasma A KG.
Say that simply mensuration is to carry out in the working solution of 0.5mL, this solution comprises 100mmol/L phosphate buffer (pH 7.6), 4mmol/L ammonium chloride and 50 μ mol/L NADH.
In described working solution, add an amount of blood plasma of the AKG that contains 1-10nmol.
Under the 340nm wavelength, obtain initial absorption reading.
After described initial absorption reading, in each test tube, add the cattle GDH (G2501 of about 6 units (volume is 10 μ L); Sigma-Aldrich, St.Louis, MO).
After cultivating 10 minutes, under the 340nm wavelength, obtain second and absorb reading.
In the sample content of AKG directly with first and second readings between absorb weaken and be directly proportional.
By using standard curve to calculate AKG concentration.
Plasma ammonia is measured
Plasma ammonia is to use the spectrophotometry test kit, and (St.Louis MO) measures for 171C, Sigma-Aldrich.
Plasma glucose is measured
Plasma glucose is to use spectrophotometry test kit (315-100; Sigma-Aldrich, St.Louis MO) measures.
The blood bicarbonate is measured
In order to estimate the concentration of blood bicarbonate, with whole blood etc. duplicate samples (1.0mL) be placed on 10-mL Vacutainer (Becton Dickinson, Franklin Lakes, NJ) in, and add the perchloric acid (10%wt/wt) of 0.5mL.
Will be by soda lime (Sodasorb; Grace Container Products, Lexington, MA) filtering room air (10mL) injects Vacutainer, is drawn in the air-tightness syringe, and puts into second Vacutainer.
The isotopes concentration of carbon dioxide is than mass spectrograph (ANCA at the continuous-flow gas isotope in the gaseous sample; Europa Instruments, Crewe U.K.) upward measures.
The mensuration of blood plasma ketoisocaproate
Blood plasma ketoisocaproate (KIC) be by cation-exchange chromatography (AG-SOV resin, Bio-Rad) isolating.
With sodium hydroxide (100 μ L; 10N) with azanol HCl (200 μ L; 0.36M) handle eluent, and heat (60 ℃; 30 minutes).After cooling, the pH of sample is adjusted to<2.
With the ethyl acetate extraction keto acid of 5mL, and dry at ambient temperature in nitrogen.
The derivatization of KIC is to finish by the N-methyl-N-t-butyl-dimetylsilyl-trifluoroacetamide that adds 50 μ L+1%t-butyl-dimethyl chlorosilane.
By EI GC-MS (Hewlett Packard 5970GC-mass spectrograph is equipped with HewlettPackard 5890 Series II GC), under the condition of 316m/z and 317m/z, pass through the isotopes concentration of monitoring ion measurement KIC.
The mensuration of carbamide isotopes concentration
By EI GC-MS assay determination blood plasma carbamide isotopes concentration.
With the iced acetone protein precipitation from the blood plasma of 50 μ L of 200 μ L.
After vortex stirs, by centrifugalize albumen, and take out supernatant, dry under nitrogen.
In described exsiccant supernatant, add 1: 20 diluent and the concentrated HCl (30wt%) of the propionic aldehyde bid (dimethyl-acetal) of 250 μ L.At room temperature cultivated described sample 2 hours, be evaporated to then drying (Speedvac, Savant Insturments, FormaScientific, Marietta, OH).
N-methyl-N-t-butyl-dimetylsilyl-trifluoroacetamide+1%t-butyl-dimethyl chlorosilane with 50 μ L carries out derivatization to described carbamide, and uses EI GC-MS to analyze by monitoring ion measurement blood plasma isotopes concentration under the condition of 153-155m/z.
Calculate
The clean portal vein balance of metabolite [μ mol/ (kg h)] is calculated by the following method:
(Conc.
PORT-Conc.
ART)×PBF (1)
When Conc. was haemoconcentration (μ mol/L), PORT and ART represented portal vein and arterial blood, and PBF is portal vein flow [L/ (kg h)].
Calculate the whole leucine flow of whole blood [Q by the following method; μ mol/ (kg h)]:
Q=R*[(IE
Inculcate notes/ IE
Blood plasma)-1] (2)
R is tracer infusion rate [μ mol/ (kg h)], and IE
Inculcate notesAnd IE
Blood plasmaBe respectively the tracer inculcated and the isotopes concentration (being expressed as mol%) of Plasma K IC.
Health CO
2Output is calculated as follows:
Wherein, IE inculcates that to annotate be to inculcate H in the notes
13CO
3 -The concentration of (molar percentage that exceeds), IE tremulous pulse bicarbonate is the concentration (molar percentage that exceeds) in the arterial blood, and each the processing stage tracer infusion rate e[μ mol/ (kg h) during the intravenous perfusion bicarbonate that carries out].Whole formula is divided by 0.82, so that proofread and correct the recovery of the labelling carbon in the bicarbonate of inculcating.
Whole leucine oxidation [μ mol/ (kg h)] is calculated by the following method:
[IE
C02/ IE
KIC] * formula 3 (4)
Wherein, IE
CO2Be at 1-
13The isotopes concentration of bicarbonate during the C-leucine is inculcated, and IE
LEUBe at 1-
131-during the C-leucine is inculcated
13The isotopes concentration of C-KIC.
It is to being incorporated into the leucic estimation in the muscle that whole non-oxide leucine is handled (NOLD).NOLD[mol/ (kg h)] calculate by following formula:
NOLD=formula 2-formula 4 (5)
Whole leucine occurrence rate (Ra) [mol/ (kg h)] is to the metabolic estimation of albuminolysis, and calculates as follows:
Ra=formula 2-leucine picked-up (6)
Whole carbamide flow calculates as follows:
The carbamide flow=[([
15N
2] carbamide IE/[
15N
2] carbamide PE)-1] * [
15N
2] carbamide IR (7)
Wherein, IE inculcates notes concentration, and PE is the plasma concentration under the steady statue during the infusion carbamide, and IR is an infusion velocity.
Statistical analysis
Concerning all statistical test, 0.05 p value is used to indicate significance,statistical.
In example 1, AKG is to tremulous pulse, pylic effect, and single amino acids, AKG, glucose, analyzing appears in the dynamic (dynamical) clean portal vein of ammonia and leucine, use the general linear model method (Minitab.Inc., State College, PA).Described model comprises the effect and the pig of adding AKG.Pig is included as stochastic variable.Use LSMEANS option computing meansigma methods.Utilize the clean portal vein balance of unidirectional Student ' s T inspection AKG whether obviously greater than the null value during control treatment.
Example 1-plasma A KG, glucose, ammonia, the measurement of blood flow and whole carbamide flow.
Purpose
The purpose of present embodiment is to assess the AKG infusion to plasma A KG, glucose, ammonia, the influence of blood flow and whole carbamide flow.
Zoopery
Before this experiment of beginning, deprive the food 15 hours of piglets.
Testing the same day,, begin continuous duodenum and pour into preprepared milk replacer [Litter Life, Merrick, Middleton, WI at-1 hour; 7.75mL/ (kgh)] (7.75mL/kg; The 25%wt/wt aqueous solution; Oral), it is as the preparation of 25% (wt/wt) aqueous solution, and it can provide about 920kJ and 12.5g albumen/(kg d).
With saline (contrast; 930mmol/L NaCl) or sodium-AKG (Na-AKG), 930mmol/L, available from Sigma-Aldrich, St.Louis MO) is dissolved in the described milk replacer.
According to former data (6), select AKG content by the laboratory of outside, wherein,, need picked-up to surpass 2.5% diet dry in order to observe detectable AKG portal vein balance.
Pig is also accepted
15N
2Successive 6 hours infusions (98% of intravenous (200 μ mol/kg) of-carbamide [20 μ mol/ (kg h)]; Cambridge Isotope Laboratories).
In the 0h time, begin 2 hours successive NaH
13CO
2Preprepared (the 15 μ mol/ (kg h) of infusion (15 μ mol/kg); 99%; Cambridge IsotopeLaboratories, Andover, MA).
At beginning NaH
13CO
2Obtain the tremulous pulse sample in 0,90,105 and 120 minutes after the infusion, be used to measure whole CO
2Output.
At 2 hours, stop NaH
13CO
2Infusion, and beginning 1-
13C-leucine (40 μ mol/ (kg h); 99%; Cambridge Isotope Laboratories) continuous 4 hours infusions preprepared (40 μ mol/kg h).
Obtain tremulous pulse and portal vein sample at 4,5 and 65 hours, be used to measure leucine and carbamide kinetics, and ammonia, AKG, glucose and amino acid whose mass balance.
All pigs all accept contrast in the mode of completely random design and AKG handles, and the interval is at least 24 hours between handling.
The result
Plasma A KG has been shown, glucose, ammonia, blood flow and whole carbamide flow in table 1.
Show the 1.AKG infusion to metabolite concentration, clean portal vein balance and whole 1-
13The C-leucine and
15N
2-carbamide effect of kinetics.
1AKG, the o ketoglutaric acid;
2SEM
[(930 μ mol/ (kg.h)) improved (P<0.01) tremulous pulse and portal vein AKG concentration to the AKG infusion, and the clean portal vein balance of AKG.Even not having AKG to beat under the duodenal situation, the clean portal vein of AKG absorbs [19.7 ± 2.8 μ mol/ (kg.h)] also significantly greater than 0.But, compared with the control, handle the clean portal vein that has significantly improved AKG with AKG and absorb (P<0.001).The clean portal vein balance of AKG is 95 μ mol/ (kg.h), and it only is equivalent to 10.23% of infusion amount.
10.23% clean portal vein balance has been over-evaluated the AKG that inculcates in fact slightly and has been absorbed, because when only inculcating saline, exists the statistics of AKG significantly to absorb.If according to control diet gauged words are carried out in the absorption of AKG, the ratio of the AKG that inculcates that occurs in portal vein is drained is reduced to 8.12%.
What is interesting is, handle, reduced the clean portal vein balance (P<0.05) of glucose with AKG.The influence that portal vein flow, clean portal vein balance of ammonia and whole carbamide flow are not handled by AKG.
Handle by AKG, tremulous pulse and pylic concentration of proline have improved (P<0.05), and the portal vein leucine tends to (P<0.01) increase (data are not delivered).Amino acid whose portal vein mass balance has been shown in table 2.AKG handles and has improved leucine, the portal vein mass balance of lysine and proline (P<0.05), and tend to the portal vein mass balance that (P<0.10) improves isoleucine.
The amino acid whose clean portal vein balance of the pig of the duodenum infusion of table 2. acceptance 0 or 930 μ mol/ (kg h) AKG (n=5).
aDifference (P≤0.05) with contrast;
bDifference (P<0.10) with contrast
1AKG, α-Tong Wuersuan;
2LS meansigma methods ± SEM
Whole leucine kinetics as shown in Figure 1.Whole flow NOLD, the influence that Ra and oxidation are not handled by AKG.
The average enteric cavity that example 2-measures AKG disappears
Purpose
The purpose of present embodiment is that the average enteric cavity of assessing the AKG medicine group that inculcates disappears.
Zoopery
(LitterLife Merrick) carries out duodenum medicine group to pig (n=7) and inculcates (7.75mL/kg with the liquid formula that contains 25mg/mL AKG sodium (1040 μ mol/kg BW); 25% (wt/wt) aqueous solution).
After 1 hour, slaughter pig.
Carefully small intestinal is clamped at duodenum near-end and caecum far-end, taken out, and with 2 * 50mL normal saline washing, so that clean small intestinal.
Collect cleaning mixture, merge, and with 15mL etc. duplicate samples quick freezing in liquid nitrogen, and preserve down at-80 ℃, the AKG that is used for subsequently analyzes.
The result
Inculcate the AKG medicine group of 1040 μ mol/kg.Average enteric cavity disappearance is 663 ± 38 μ mol/kg in 1 hour.63.8 of the 1040 μ mol/kg AKG that this is equivalent to inculcate.
The discussion and the common conclusions of experiment 1 and 2
In example 1, the AKG continuous irrigation is passed in the duodenum, and has only 10% the AKG that inculcates to appear in the portal vein discharge liquor.
Have only 10% the AKG that inculcates to appear at the some kinds of probabilities that this discovery in the portal vein blood plasma has produced the destiny of enteric cavity AKG.A kind of possible explanation that low AKG portal vein is occurred is that enteric cavity AKG transhipment is limited.Sodium/dicarboxylic acids can be transported the cotransporter of AKG, and it is present in (9) on the pig brush border membrane, as if therefore, AKG can be absorbed by enterocyte.In order to verify this probability, we have inculcated the single medicine of the duodenum group of 1040 μ mol/kg, and find to surpass 660 μ mol/kg disappeared from the small intestinal of piglets in 1 hour (example 2).Therefore, about 64% AKG medicine group is only just disappearing in duodenal enteric cavity within an hour.
The influence (6) of AKG infusion appears not being subjected to as the clean portal vein of former viewed glutamic acid and glutamine.If the AKG that absorbs changes into glutamic acid, it can be discharged in the portal vein blood or change into other aminoacid.
But, can estimate that the release of glutamic acid and glutamine can not increase because of AKG, even occurred to these amino acid whose remarkable conversions, because under normal raising condition, seldom there are food glutamic acid or glutamine to discharge (list of references 1,2) by PDV.Verified (10), proline can be synthetic by enteral glutamic acid by intestinal tissue.Suppose in the pig that AKG handles, the equilibrated 138.1 μ mol/ (kg h) that increase to of the clean portal vein of proline, and the AKG that surpasses 800 μ mol/ (kg h) does not participate in the portal vein balance, and the clean portal vein balance of proline is because the conversion of AKG causes probably fully.But, AKG should cause the reduction of portal vein nitrogen balance to this extensive conversion of proline in intestinal cell, and still, the portal vein nitrogen balance remains unchanged.Shortage to the influence of portal vein nitrogen balance is embodied on the similar speed of whole urea synthesis in two groups equally.
Reaction between branched-chain amino acid (BCAA) transaminase energy catalysis AKG and the branched-chain amino acid (leucine, isoleucine and valine).BCAA is changeed ammonia, forms glutamic acid by AKG, and forms corresponding keto acid by BCAA.The AKG that replenishes may form glutamic acid and cause the minimizing to the clean release of BCAA by PDV by the transamination that promotes BCAA.But, AKG can increase leucic portal vein and discharge, but it can not influence whole leucine kinetics.The clean portal vein balance of lysine also can improve with AKG.Because handle concerning a lot of aminoacid with AKG, a lot of amino acid whose clean portal vein balances are near 100%, and unclear is because AKG has saved described aminoacid or owing to the Proteolytic enzyme in the internal organs of portal vein-drain has increased amino acid whose release.
The destiny of the another possibility of AKG in enterocyte is by the TCA cyclic oxidation.If all carbon of inculcating with the AKG form is oxidized to CO
2, can estimate to increase CO by PDV
2Output, yet CO on the whole
2Output do not increase because AKG inculcates.What is interesting is, handle that by AKG the clean portal vein balance of glucose has been reduced.
Because a large amount of AKG has disappeared from the enteric cavity of small intestinal, and do not cause the portal vein drainage of AKG or the clean balance of the metabolic amino acid product of AKG, the destiny of the AKG of intestinal picked-up it be unclear that.But, when AKG is beaten into duodenum, have only 10% enteric cavity quantity delivered to appear in the portal vein discharge liquor, yet the AKG of this quantity is enough to improve the circulation composition of portal vein balance and described chemical compound.Therefore, although the definite metabolism destiny of AKG in enteric cavity is still uncertain, described result shows that the intestinal utilizability of diet AKG is limited.
The increase of the circulation A KG that is caused is to glutamic acid, glutamine, and ammonia, not influence appears in the clean portal vein of BCAA.
In addition, increase the AKG of system to PDV or whole leucine kinetics or the not influence of carbamide flow.The above results and former data are coincide, and wherein, AKG provides by the gastrointestinal tract approach.
Na-AKG and chitosan-AKG that example 3-intestinal is used inhale aminoacid and keto acid
Receive in enterocyte and the blood plasma, and the comparison of their metabolic effect
Purpose
The purpose of present embodiment is that the Na-AKG (or Na salt of AKG) that uses of comparison intestinal and chitosan-AKG are to absorbing aminoacid and keto acid and their metabolic effect in enterocyte and the blood plasma.In addition, by monitoring of blood blood plasma amino acid content mensuration Na-AKG and chitosan-AKG keto acid is changed into amino acid whose influence.This research has been checked AKG to influence keto acid and has been transformed and improve the synthetic hypothesis of albumen to amino acid whose intestinal.
Zoopery
To have three pigs altogether and be used for this experiment.The body weight of these pigs is approximately 20kg.These pigs separately are housed in the box, and feed standard food 4-5 days, so that adapt to new facility.Insert intubate and intestinal sleeve pipe by operation to pig then, and recovered with 3-7 days time.The operation method that is adopted is the method that is usually used in this area, and is conventionally known to one of skill in the art.
After operation, under this occasion, allow 3 days convalescent period, and use standard feed (3% body weight) feed once (10.00) every day.After convalescent period, using Na-AKG ((ii)) referring to experiment, use chitosan-AKG (experiment is (iii)) and do not use AKG (experiment (i)); Control experiment) measures the amino acid content in the blood plasma under the condition, further details is provided below.
The AKG application conditions:
Experiment (i): inculcate (i.d.) by duodenum, use keto acid or aminoacid (amine) (cumulative volume is 50ml), * " feed equivalent in early morning " 1 hour.
Provided 10 parts, (50ml dosage+50ml saline) with 1 hour.
It represents control experiment.
(described animal obtains and the aminoacid that is present in the same amount in the food that is equivalent to the feedstuff in early morning usually in * " feed equivalent in early morning " expression).Blood sample (being background * * level in the time of 0 hour) is 0,1,2, and 4 disappearances are gathered.
(* * background sample is defined in aminoacid/keto acid and inculcates the sample of 0 time before)
Blood sample (the 5ml whole blood is used for amino acid analysis, from tremulous pulse, and portal vein, hepatic vein is captured on the ethylenediaminetetraacetic acid (EDTA) that contains aprotinin, so that stop blood coagulation and proteinase activity.
(processing method relates to 5 EDTA+ aprotiniies of use, and is centrifugal, and-20 ℃ of following frozen plasma).
Experiment (ii)
Inculcate (i.d.) by duodenum and use and blended keto acid of Na-AKG or aminoacid (amine) (cumulative volume is 50ml), dosage is * " feed equivalent in early morning ", with 1 hour time (provided 10 parts with 1 hour time, 50ml dosage optionally uses saline).
0,1,2,4 hours collection blood samples (in the time of 0 hour, being background level).
Blood sample (the 5ml whole blood is used for amino acid analysis, from tremulous pulse, portal vein, hepatic vein) is captured on the ethylenediaminetetraacetic acid (EDTA) that contains aprotinin, so that stop blood coagulation and proteinase activity.
Experiment (iii)
Inculcating (i.d.) by duodenum uses and blended keto acid of chitosan-AKG or aminoacid (amine) (cumulative volume is 50ml), dosage is * " feed equivalent in early morning ", with 1 hour time (provided 10 parts with 1 hour time, 50ml dosage optionally uses saline).
0,1,2,4 hours collection blood samples (in the time of 0 hour, being background level).
Blood sample (the 5ml whole blood is used for amino acid analysis, from tremulous pulse, portal vein, hepatic vein) is captured on the ethylenediaminetetraacetic acid (EDTA) that contains aprotinin, so that stop blood coagulation and proteinase activity.
The result
The result of following this research of table 3 expression:
Table 3. is the increment of free amino acid increase in the blood after using aminoacid:
Time (hour) | ΔI(mmol/L) | ΔII(mmol/L) | ΔI(mmol/L) | ΔII(mmol/L) |
Tremulous pulse | Tremulous pulse | Hepatic vein | Hepatic vein | |
1 | -0.5 a | 0.65 c | 0.43 A | 0.23 A |
1.5 | 0.04 b | 1.11 d | 1.61 B | 1.85 BC |
2.5 | -0.48 a | 1.69 d | 1.59 B | 1.94 C |
I represents Na-AKG salt
II represents chitosan-AKG salt
Delta time increment=(at the Δ aminoacid of 0 time-) at 1,1.5 and 2.5 hour amino acid content
Provide result's difference to represent significant difference when the p<0.05 with the lower case or upper case letter.
The discussion of example 3 and general conclusion
Present embodiment has confirmed that chitosan-AKG salt can improve the absorption of essential amino acids, and this improvement is better than the result who obtains with Na-AKG.
This discovery is important, and with the gastrointestinal tissue that diet aminoacid is used to improve better impaired, for example, the amino acid whose absorption that is common in diabetes or old people patient's the gastrointestinal tissue is relevant.
Claims (19)
1.AKG AKG analog or the preparation of its mixture are used to prevent, alleviate or treat the purposes of the compositions of vertebrate high plasma glucose symptom.
2. purposes as claimed in claim 1, wherein, described AKG, AKG analog or its mixture are selected from following one group: AKG, ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, chitosan-AKG, AKG and amino acid whose salt; One of AKG-and two-slaine.
3. purposes as claimed in claim 1, wherein said AKG, AKG analog or its mixture are selected from CaAKG, Ca (AKG)
2And NaAKG.
4. purposes as claimed in claim 1, wherein, described vertebrates is a rodent, birds, farm animal or house pet.
5. purposes as claimed in claim 4, wherein said rodent are mice, rat, Cavia porcellus or rabbit; Described birds is turkey, hen, chicken or other chickling; Described farm animal is cow, horse, pig, piglets or the farm animal of freely walking about; Described house pet is Canis familiaris L. or cat.
6. purposes as claimed in claim 1, wherein, described vertebrates is human.
7.AKG AKG analog or its mixture production are used to reduce the purposes of the compositions that the vertebrates plasma glucose absorbs.
8. purposes as claimed in claim 7, wherein said AKG, AKG analog or its mixture are selected from AKG, ornithine-AKG, arginine-AKG, glutamine-AKG, glutamic acid-AKG, leucine-AKG, chitosan-AKG, AKG and amino acid whose salt; One of AKG-and two-slaine.
9. purposes as claimed in claim 8, wherein said AKG, AKG analog or its mixture are selected from CaAKG, CaAKG
2And NaAKG.
10. purposes as claimed in claim 7, wherein, described vertebrates is a rodent, birds, farm animal or house pet.
11. as the purposes of claim 10, wherein said rodent is mice, rat, Cavia porcellus or rabbit; Described birds is turkey, hen, chicken or other chickling; Described farm animal is cow, horse, pig, piglets or the farm animal of freely walking about; Described house pet is Canis familiaris L. or cat.
12. purposes as claimed in claim 7, wherein, described vertebrates is human.
13. as each purposes of claim 1-12, wherein said high plasma glucose symptom is a type i diabetes.
14. as each purposes of claim 1-12, wherein said high plasma glucose symptom is a type ii diabetes.
15. as each purposes of claim 1-12, wherein said compositions is a Pharmaceutical composition, optionally comprise can be medicinal carrier and/or additive.
16. as purposes any among the claim 1-12, wherein, described compositions is food or feed additive.
17. as the purposes of claim 16, wherein, described food or feed additive are the compositions of food additive and/or solid food and/or drink form.
18. as purposes any among the claim 1-12, wherein, in the compositions of described production, described AKG, AKG analog or its mixture treat effective dose.
19. as the purposes of claim 18, wherein, described treatment effective dose is 0.01-0.2g/kg body weight dosage every day.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301947-8 | 2003-07-01 | ||
SE0301947A SE0301947D0 (en) | 2003-07-01 | 2003-07-01 | New method and uses |
US60/481,301 | 2003-08-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800203227A Division CN1822827B (en) | 2003-07-01 | 2004-07-01 | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101301285A true CN101301285A (en) | 2008-11-12 |
Family
ID=27731075
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100926372A Pending CN101301285A (en) | 2003-07-01 | 2004-07-01 | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
CN2004800203227A Expired - Fee Related CN1822827B (en) | 2003-07-01 | 2004-07-01 | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800203227A Expired - Fee Related CN1822827B (en) | 2003-07-01 | 2004-07-01 | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4847323B2 (en) |
CN (2) | CN101301285A (en) |
SE (1) | SE0301947D0 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028102A (en) * | 2010-12-08 | 2011-04-27 | 江南大学 | Natural and safe growth-type feed additive |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104304685A (en) * | 2014-11-14 | 2015-01-28 | 中国水产科学研究院黑龙江水产研究所 | Feed additive for increasing protein utilization rate of sturgeon feed and addition method of feed additive |
CN105231038A (en) * | 2015-09-23 | 2016-01-13 | 华南农业大学 | Application of alpha-oxoglutarate in respect of preparing pig feed additive |
CN105941912A (en) * | 2016-05-16 | 2016-09-21 | 华南农业大学 | Application of alpha-ketoglutaric acid and alpha-ketoglutarate in preparation of feed additive capable of improving pig carcass composition |
CN107616505B (en) * | 2017-10-24 | 2020-12-25 | 精晶药业股份有限公司 | A health product containing ornithine ketoglutarate and its preparation method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE462463B (en) * | 1988-12-02 | 1990-07-02 | Decken Alexandra V D | FOOD AND FEED CONTAINING KETOS ACIDS |
SE9201584D0 (en) * | 1992-05-20 | 1992-05-20 | Vinnars Erik Ab | USE OF ALPHA KETOGLUTARATE |
SE9303691D0 (en) * | 1993-11-09 | 1993-11-09 | Gramineer Ab | New beverage |
JPH10175855A (en) * | 1996-10-16 | 1998-06-30 | Taisho Pharmaceut Co Ltd | Physical fatigue relieving agent |
ATE555780T1 (en) * | 1997-10-24 | 2012-05-15 | John P Blass | DIETARY SUPPLEMENTS FOR METABOLIC BRAIN DISORDERS |
DE19755367C2 (en) * | 1997-12-12 | 2001-03-22 | Afting Ernst Guenter | Pharmaceutical composition containing D-galactose and its use |
NL1014380C2 (en) * | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Intestinal wall-strengthening food. |
SE0201713D0 (en) * | 2001-11-23 | 2002-06-06 | Gramineer Internat Ab | New methods and use III |
-
2003
- 2003-07-01 SE SE0301947A patent/SE0301947D0/en unknown
-
2004
- 2004-07-01 CN CNA2008100926372A patent/CN101301285A/en active Pending
- 2004-07-01 JP JP2006517059A patent/JP4847323B2/en not_active Expired - Fee Related
- 2004-07-01 CN CN2004800203227A patent/CN1822827B/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028102A (en) * | 2010-12-08 | 2011-04-27 | 江南大学 | Natural and safe growth-type feed additive |
Also Published As
Publication number | Publication date |
---|---|
JP2007529408A (en) | 2007-10-25 |
JP4847323B2 (en) | 2011-12-28 |
CN1822827B (en) | 2012-03-28 |
CN1822827A (en) | 2006-08-23 |
SE0301947D0 (en) | 2003-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Holtenius et al. | The effect of the plasma glucose level on the abomasal function in dairy cows | |
Singh | Nutritional management of patients with urea cycle disorders | |
EA033940B1 (en) | Oral rehydration solution and method for preparation thereof | |
US20100069498A1 (en) | Use of alpha-ketoglutaric acid for the treatment of high plasma glucose condition | |
CN1822827B (en) | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition | |
Selle et al. | The impact of digestive dynamics on the bioequivalence of amino acids in broiler chickens | |
Guo et al. | Role of growth hormone, glutamine and enteral nutrition in pediatric short bowel syndrome: a pilot follow-up study | |
CN102552250B (en) | Compound amino acid injection for livestock as well as preparation method and applications thereof | |
Tessari et al. | Interorgan amino acid exchange | |
Reynolds et al. | Effects of mesenteric vein n-butyrate infusion on liver metabolism by beef steers | |
CN101027063B (en) | Use of difructose anhydride for preparation drug | |
CN108348495A (en) | Treating diabetes composition | |
Watanabe et al. | Maturational changes and origin of urinary human epidermal growth factor in the neonatal period | |
WO2009123029A1 (en) | Blood ammonia level regulator | |
Savary et al. | Lysine metabolism across the hindquarters of sheep; effect of intake on transfers from plasma and red blood cells | |
Kapila et al. | Arginine deficiency‐induced hyperammonemia in a home total parenteral nutrition‐dependent patient: a case report | |
Thomas et al. | Control of renal solute excretion by enteric signals and mediators | |
Zicker et al. | Concentrations of amino acids in the plasma of neonatal foals with septicemia | |
Song et al. | The hepatic extraction of plasma free amino acids and response to hepatic portal venous infusion of methionine sources in anesthetized SCWL males (Gallus domesticus) | |
JP3556757B2 (en) | Absorption-promoting saccharide composition | |
JP5076327B2 (en) | Adaptation of branched-chain amino acids to heart failure | |
Simell et al. | Transport defects of amino acids at the cell Membrane: Cystinuria, Hartnup Disease, and lysinuric protein intolerance | |
JP5477413B2 (en) | Adaptation of branched-chain amino acids to heart failure | |
JP2012236820A (en) | Composition for preventing or treating chronic kidney disease | |
Seegraber | The effect of soy protein on digestibility of calf milk replacers and on intestinal absorptive ability as determined by the xylose absorption test |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1124553 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081112 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1124553 Country of ref document: HK |